Paradigm Biopharma (PAR) listed on the ASX in August 2015. Paradigm Biopharma's focus is on repurposing pentosan polysulphate sodium (PPS) for the treatment of diseases sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties. 

Pharmaceutical

Paradigm Biopharma

Paradigm Biopharma's headquarters in Melbourne, Australia

Paul Rennie

Samantha H.

Jill Forrest

Simon White

Donna Skerrett

Michelle Coffey

John Gaffney

Amos Meltzer

Kevin Hollingsworth

Description

People (3)

Paul Rennie

Simon White

Samantha H.

Jobs